You may see a range of opinions about GLP-1 agonists for weight loss on the internet. Social media can be a great place to learn about people’s experiences taking semaglutide and similar medications. At the same time, you may also find a lot of misinformation or opinions that fuel stigma.
In this video, learn tips for navigating the internet when researching GLP-1 agonists for weight loss, according to Preeti Parikh, MD, Executive Medical Director at GoodRx.
Preeti Parikh, MD is the Executive Medical Director at GoodRx and served as the Chief Medical Officer of HealthiNation.
References
Abrams, Z. (2022). The burden of weight stigma. American Psychological Association.
Collins, L., et al. (2023). Glucagon-like peptide-1 receptor agonists. StatPearls.
Latif, W., et al. (2023). Compare and contrast the glucagon-like peptide receptor agonists (GLP1RAs). StatPearls.
Suarez-Lledo, V., et al. (2021). Prevalence of health misinformation on social media: Systematic review. Journal of Medical Internet Research.
U.S. Department of Health and Human Services. (2023). Health misinformation.
Why trust our experts?
